7*24 Hotline：
Microchip bio is a bio high-tech enterprise founded by a senior team from the United States, specializing in the research and development of original small molecule drugs. The original team and local team have high scientific attainments in biomedical research, practical experience in R & D and management of innovative drugs, successful experience in establishing and managing enterprises in Europe and America, familiar with global drug management technical regulations and patent strategies, and familiar with Chinese drug market.
The core technology to support the company's sustainable development is our self built integrated drug innovation and early evaluation technology system based on chemical genomics. The platform system effectively integrates a number of modern technologies, including computer-aided drug design, drug and combinatorial chemistry, high-throughput and high-content drug screening, chemical genomics gene expression profile research, bioinformatics and chemical informatics data mining. It can effectively accelerate the research and development process of small molecule innovative drugs, reduce the risk of new drug development, and is the key to the research and development of clinically different drugs It is an important technology of chemical new drugs, and also an important guarantee to support the sustainable development of micro core biology in the future.
According to the law of international R & D of new drugs and the current situation of Chinese pharmaceutical market, microchip bio has explored a way of enterprise development, which not only retains the rights and interests of Chinese products, but also implements patent authorization for international pharmaceutical companies, establishes international clinical joint development and realizes profits; at the same time, establishes a high-level cooperative research business model with multinational pharmaceutical enterprises. Through this development strategy, we can not only launch new drugs in China as soon as possible, but also realize the goal of Chinese original drugs entering the global market through the mode of international clinical joint development. This innovative development model, which realizes profit and development through patent authorization, cooperative research and final marketing of products, has changed the substantive defect of lack of original drugs in Chinese local pharmaceutical enterprises, and created a precedent from "Chinese imitation" to "Chinese creation".
Since its establishment, the company has made breakthrough progress in new drug research and development, intellectual property rights, business development and other aspects around the establishment of the enterprise development strategy with patents and innovative drugs as the core competitiveness. It has achieved the first place in many industries and made positive contributions to China's innovative drug industry.
Microchip biology has a complete ability from drug target research to clinical candidate drug development and industrialization. It has also successfully cultivated a rare technology and management team specializing in the research and development of new chemical structure innovative drugs in China, which has become a guarantee for our independent intellectual property rights as the core, for major diseases, global patent protection and clinical effect independence Special innovation of small molecule chemical drugs and the core advantages of enterprise growth.
oil wellhead